Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 0 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Saranya Chidambaranathan ReghupatyC. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA.
Sadia KanwalFood and Nutrition Science Laboratory, College of Agriculture, Virginia State University, Petersburg, VA 23806, USA.
Rachel G MendozaDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Eva DavisDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Haiwen LiFood and Nutrition Science Laboratory, College of Agriculture, Virginia State University, Petersburg, VA 23806, USA.
Zhao LaiGreehey Children's Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Mikhail G DozmorovDepartment of Biostatistics and Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-0086-8358
Milton Omar FaisonDepartment of Biology, Virginia State University, Petersburg, VA 23806, USA.
Rafat Ali SiddiquiFood and Nutrition Science Laboratory, College of Agriculture, Virginia State University, Petersburg, VA 23806, USA.ORCID 0000-0001-5936-1239
Devanand SarkarDepartment of Human and Molecular Genetics, Massey Cancer Center, VCU Institute of Molecular Medicine (VIMM), Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0003-0973-2323
Virginia Commonwealth University · USVirginia State University · USThe University of Texas Health Science Center at San Antonio · US
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
The role of AEG-1 in NASH and NASH-HCCR01DK107451 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND · 2016 to 2025
$3.9M
Novel Targeted Combinatorial Therapy for Hepatocellular CarcinomaR01CA244993 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B, SARKAR, DEVANAND · 2020 to 2024
$2.7M
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinomaR01CA240004 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND, WANG, XIANG-YANG SHAWN · 2019 to 2023
$2.4M
Targeting oncogenes for hepatocellular carcinomaR01CA230561 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND · 2019 to 2023
$2.0M
SUCCEED Cancer Research Education Program (CREP)P20CA264067 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI WINN, ROBERT A. · 2021 to 2024
$845k
SUCCEED Pilot Project 2P20CA264068 · NCI · VIRGINIA STATE UNIVERSITY · PI FAISON, MILTON O · 2021 to 2024
$843k
High Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
African-American (AA)/Black hepatocellular carcinoma (HCC) patients have increased incidence and decreased survival rates compared to non-Hispanic (White) patients, the underlying molecular mechanism of which is not clear. Analysis of existing RNA-sequencing (RNA-seq) data in The Cancer Genome Atlas (TCGA) and in-house RNA-sequencing of 14 White and 18 AA/Black HCC patients revealed statistically significant activation of type I interferon (IFN-I) signaling pathway in AA/Black patients. A four-gene signature of IFN-stimulated genes (ISGs) showed increased expression in AA/Black HCC tumors versus White. HCC is a disease of chronic inflammation, and IFN-Is function as pro-inflammatory cytokines. We tested efficacy of ginger extract (GE), a dietary compound known for anti-inflammatory properties, on HCC cell lines derived from White (HepG2), AA/Black (Hep3B and O/20) and Asian (HuH-7) patients. GE exhibited a significantly lower IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dysregulation of Type I Interferon (IFN-I) Signaling: A Potential Contributor to Racial Disparity in Hepatocellular Carcinoma (HCC). · full record | OpenQuestion